⌕
Acadia Pharmaceuticals · ACAD · Nasdaq
Tenet 65 · Solid
Compare
$18.32−1.87%At closeTenet 65 · Solid
$18.32−0.35 (−1.87%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Acadia Pharmaceuticals (ACAD) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~22.0%/yr (FY21→FY25), net margin 36.5%; free cash flow runs at 27% of net income. Check the accrual gap. Worth your attention in FY25: Share count (+5.9%) and Capex step-up ($4.7M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲11.9%
1,071.5
FY21→FY25CAGR +22.0%/yr
Net income ($M)▲72.7%
391.0
one-off year: see footnoteCAGR —
Free cash flow ($M)▼33.1%
105.1
capex stepped upCAGR —
Diluted EPS▲69.1%
2.30
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+5.9%

160.5mn → 169.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$4.7M

▲797% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)1071.5Revenue−89.0COGS982.5Gross profit−328.8R&D−548.9SG&A104.8Op income286.2Tax & other391.0Net income

36¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 96.0% → 91.7%. Net margin 36.5% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,202,301.01,071,505.0957,797.0726,437.0517,235.0484,145.0▲11.9%+22.0%
Cost of revenue
114,422.088,998.081,841.041,638.010,166.019,141.0▲8.7%+46.8%
Gross profit
1,087,879.0982,507.0875,956.0684,799.0—A465,004.0▲12.2%—
Research & development
319,462.0328,802.0303,249.0351,619.0361,575.0239,415.0▲8.4%+8.3%
Selling, general & admin
646,088.0548,894.0488,428.0406,559.0369,090.0396,028.0▲12.4%+8.5%
Total operating expenses
965,550.0877,696.0645,162.0758,178.0730,665.0635,443.0▲36.0%+8.4%
Operating incomefeeds ROC rank
122,329.0104,811.0230,794.0−73,379.0−223,596.0−170,439.0▼54.6%—
Other income, net
34,883.034,093.027,281.022,343.010,152.02,920.0——
Pretax income
157,212.0138,904.0258,075.0−51,036.0−213,444.0−167,519.0▼46.2%—
Income tax
−205,017.0−252,096.031,624.010,250.02,531.0351.0——
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
362,229.0391,000.0226,451.0−61,286.0−215,975.0−167,870.0▲72.7%—
Per share
Diluted EPSbuyback-sensitive
2.122.301.36−0.37−1.34−1.05▲69.1%—
Diluted shares (mn)
175.47169.92166.36163.82161.68160.49▲2.1%+1.4%
Margins
Gross margin86th pct in Healthcare
90.5%91.7%91.5%94.3%—A96.0%▲0.2pp—
Operating margin
10.2%9.8%24.1%−10.1%−43.2%−35.2%▼14.3pp+45.0pp
Net margin95th pct in Healthcare
30.1%36.5%23.6%−8.4%−41.8%−34.7%▲12.8pp+71.2pp
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was −20% vs a −1% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was 12% vs a −1% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Acadia Pharmaceuticals' revenue last fiscal year?

Acadia Pharmaceuticals reported revenue of $1,071.5M in fiscal 2025, up 11.9% from fiscal 2024.

What was Acadia Pharmaceuticals' net income?

Acadia Pharmaceuticals reported net income of $391.0M in fiscal 2025, a net margin of 36.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.